Advaxis (NASDAQ:ADXS) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Advaxis Stock Up 9.6 %

ADXS opened at $2.85 on Monday. Advaxis has a twelve month low of $1.00 and a twelve month high of $13.12.

Advaxis Company Profile

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.